Abstract
TBE vaccination strategies capable of inducing strong paediatric immunogenicity and acceptable reactogenicity are still under evaluation. This single-blind, multi-center, randomized, controlled, phase III clinical study compared the immunogenicity and safety of the two paediatric TBE vaccines available in Europe (FSME-IMMUN (R) Junior and Encepur (R) Children) following administration of two doses of either vaccine in 303 children aged 1-11 years.
Regardless of immunological test or viral antigen used, immunological responses were consistently higher in children vaccinated with FSME-IMMUN (R) Junior than those vaccinated with Encepur (R) Children. FSME-IMMUN (R) Junior is also non-inferior to Encepur (R) Children.